Target intelligence / Profile preview

COP9 signalosome complex subunit 5 (COPS5) (COPS5)

Target
COPS5
Molecular classification
Enzyme, Metalloprotease, COP9 signalosome subunit
01

Overview

The Jab1/p21 pathway refers to the regulatory axis where Jun activation domain-binding protein 1 (Jab1), also known as COP9 signalosome complex subunit 5 (COPS5), mediates the degradation of the cyclin-dependent kinase inhibitor p21 (Cip1/Waf1) [1, 2]. Jab1 acts as the catalytic subunit of the COP9 signalosome, possessing isopeptidase activity that removes Nedd8 from Cullin-RING ligases (CRLs), a process essential for CRL recycling and subsequent substrate ubiquitination [3]. In various malignancies, Jab1 is frequently overexpressed, leading to the accelerated proteasomal degradation of p21, which normally functions to induce cell cycle arrest in response to DNA damage [4]. Consequently, the Jab1/p21 axis is a significant driver of uncontrolled cell proliferation and tumor progression. Therapeutic targeting of this pathway primarily focuses on small-molecule inhibitors of Jab1's metalloprotease activity, such as CSN5i-3, which stabilize p21 and other tumor suppressors like p27 and p53 [3]. While these inhibitors show potent anti-tumor activity in preclinical models, the central role of the COP9 signalosome in maintaining cellular protein homeostasis poses challenges regarding potential systemic toxicity and the need for precise patient stratification [3, 4].

Other names
Jun activation domain-binding protein 1Jab1CSN5SGN5Jab1/p21 axis
02

Mechanism of action

Inhibition of the isopeptidase activity of the COP9 signalosome subunit 5, preventing the deneddylation of Cullin-RING ligases and leading to the stabilization of substrates like p21 [3].

03

Biological functions

Protein degradationCell cycle regulationSignal transductionTranscription regulationDeneddylation
04

Disease associations

CancerInflammation
05

Safety considerations

Systemic toxicity due to broad protein homeostasis disruptionPotential for off-target effects on multiple Cullin-RING ligase substratesNarrow therapeutic window
06

Interacting drugs

CSN5i-3

1 more in the full profile.

07

Biomarkers

p21 expression levelsCOPS5 overexpressionCullin deneddylation status

Beyond the preview

Go deeper on COP9 signalosome complex subunit 5 (COPS5) (COPS5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on COP9 signalosome complex subunit 5 (COPS5) (COPS5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call